We are monitoring the impact of COVID-19 & Recession alarm on APAC Dendritic Cell Cancer Vaccines Market Get in touch with us for detailed analysis Know More

Know More

Share on

Asia Pacific Dendritic Cell Cancer Vaccines Market Research Report – Segmented By Product Type, End User & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore & Rest of APAC) - Industry Size, Share, Trends, Growth, Forecasts (2022 to 2027)

Published: January, 2022
ID: 5268
Pages: 145

APAC Dendritic Cell Cancer Vaccines Market Size (2022 to 2027):

The Dendritic Cell Cancer Vaccines Market size in the Asia Pacific is expected to grow at a promising rate between 2022 to 2027.

As per the National Institute of Cancer Prevention and Research, an estimated 2.25 million people in India are diagnosed with cancer, and 1,157,294 new cancer cases are being recorded annually. The growing cancer population, rising older people diagnosed with cancer, and increasing awareness among people over the treatment procedures are majorly influencing the industry growth. In addition to this, the government's growing measures to build awareness in people regarding the treatment and the availability of well-structured infrastructure are expected to drive the market further. The presence of many key players and huge investments made for the research in creating new drugs and vaccines are positive factors that boost business growth. Rising healthcare expenses, developments in advanced technologies, and betterments made for clinical trials' success rates help to have a hike in business growth.

However, adverse side-effects and some risks concerned with dendritic cells' applications are likely to curb market growth. The high cost of the treatment procedures is slowly hindering the growth rate of the market. 

This research report on the Asia Pacific Dendritic Cell Cancer Vaccines Market has been segmented and sub-segmented into the following categories:

By Product Type:

  • CreaVax
  • Sipuleucel-T (Provenge)

By End User:

  • Pediatrics
  • Adults

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Based on product type, Provenge was the first DC vaccine introduced in the market. So naturally, it follows that it is the market leader and is expected to remain so till the end of the forecast period. It treats melanoma, prostate cancer, etc. It was approved by the FDA nearly seven years ago.

Based on the region, the Asia Pacific will continue its high growth spurt till 2024. The booming economies of India and China are spearheading this spectacular growth. Countries like India and China are heading the immense growth in the dendritic cell cancer vaccine market. In India, around 4.5 lakhs people are suffering from the disease, and more than 7lakh new cases have been registering every year, and approximately 5,56,400 deaths occurred due to cancer. DENVAX is dendritic cell-based cancer immunotherapy for solid cancer in different stages of the disease. This aims the cancer cells importantly without threatening the healthy cells. It is used to control the development and slow down the spread of cancer and develop its life span. Adoption of sedentary lifestyles is expected to level up the demand of the market. The clinical trials of Phase II of dendritic cell therapy (DCT) have completely succeeded in India. Regular approvals by the U.S FDA for novel drugs and vaccines are responsible for the industry growth.

Some of the notable dominating the Asia Pacific Dendritic Cell Cancer Vaccines Market Profiled in the Report are 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation (Dendreon Corporation). Other players in the market include Elios Therapeutics. ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck & co, Northwest Biotherapeutics, Glaxo Smith Kline, ImmunoCellular Therapeutics, Tella Incorporation, and Vaxil BioTherapeutics.

1. Introduction       

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods

                1.4 General Study Assumptions                

2. Research Methodology                 

                2.1 Introduction     

                2.2 Research Phases                      

      2.2.1 Secondary Research           

      2.2.2 Primary Research 

      2.2.3 Econometric Modelling      

      2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline

3. Overview             

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology    

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)          

                4.1 Market Drivers

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market    

5. Market Segmentation                    

                5.1 Product Type   

      5.1.1 Introduction           

      5.1.2 CreaVax   

      5.1.3 Sipuleucel-T (Provenge)    

      5.1.4 Others      

      5.1.5  Y-o-Y Growth Analysis, By Product Type   

      5.1.6  Market Attractiveness Analysis, By Product Type 

      5.1.7  Market Share Analysis, By Product Type   

                5.2 End User                      

      5.2.1 Introduction           

      5.2.2 Pediatrics 

      5.2.3 Adults       

      5.2.4 Y-o-Y Growth Analysis, By End User             

      5.2.5 Market Attractiveness Analysis, By End User           

      5.2.6 Market Share Analysis, By End User             

6. Geographical Analysis                    

                6.1 Introduction     

      6.1.1 Regional Trends    

      6.1.2 Impact Analysis     

      6.1.3 Y-o-Y Growth Analysis        

                      6.1.3.1 By Geographical Area

                      6.1.3.2 By Product Type

                      6.1.3.3 By End User

      6.1.4  Market Attractiveness Analysis     

                      6.1.4.1 By Geographical Area

                      6.1.4.2 By Product Type

                      6.1.4.3 By End User

      6.1.5  Market Share Analysis      

                      6.1.5.1 By Geographical Area

                      6.1.5.2 By Product Type

                      6.1.5.3 By End User

                6.2 China   

                6.3 India    

                6.4 Japan  

                6.5 South Korea     

                6.6 Australia       

                6.7 Rest of APAC               

7. Strategic Analysis             

                7.1 PESTLE analysis                         

      7.1.1 Political     

      7.1.2 Economic 

      7.1.3 Social         

      7.1.4 Technological         

      7.1.5 Legal          

      7.1.6 Environmental       

                7.2 Porter’s Five analysis    

      7.2.1 Bargaining Power of Suppliers        

      7.2.2 Bargaining Power of Consumers    

      7.2.3 Threat of New Entrants     

      7.2.4 Threat of Substitute Products and Services              

      7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis              

                8.1 3M Company   

      8.1.1 Overview 

      8.1.2 Product Analysis   

      8.1.3 Financial analysis  

      8.1.4 Recent Developments       

      8.1.5 SWOT analysis       

      8.1.6 Analyst View          

                8.2 Activarti                       

                8.3 Argos Therapeutics                 

                8.4 Batavia Bioservices                  

                8.5 Bellicum Pharmaceuticals                     

                8.6 Creagene                    

                8.7 DanDrit Biotech                        

                8.8 DCPrime                      

                8.9 Sanpower Corporation (Dendreon Corporation)                        

                8.10 Elios Therapeutics                 

9. Competitive Landscape                 

                9.1 Market share analysis  

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, Collaborations, and Joint Ventures                         

                9.4 New Product Launches                         

10. Market Outlook and Investment Opportunities               

Appendix                 

                a) List of Tables                

                b) List of Figures    

  1. Asia Pacific Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  2. Asia Pacific CreaVax Market By Region, From 2022 - 2027 ( USD Billion )
  3. Asia Pacific Sipuleucel-T (Provenge) Market By Region, From 2022 - 2027 ( USD Billion )
  4. Asia Pacific Others Market By Region, From 2022 - 2027 ( USD Billion )
  5. Asia Pacific Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )
  6. Asia Pacific Pediatrics Market By Region, From 2022 - 2027 ( USD Billion )
  7. Asia Pacific Adults Market By Region, From 2022 - 2027 ( USD Billion )
  8. Japan Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  9. Japan Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )
  10. China Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  11. China Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )
  12. India Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  13. India Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )
  14. Australia Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  15. Australia Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )
  16. South Korea Dendritic Cell Cancer Vaccines Market By Product Type, From 2022 - 2027 ( USD Billion )
  17. South Korea Dendritic Cell Cancer Vaccines Market By End User, From 2022 - 2027 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

pdf
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample